US4093714A
Expired / Lapsed
US
⏱️ 0.0 years remaining
9β-D-Arabinofuranosylpurine nucleotides and method of use
Assignee: Viratek Inc
•
Filing: 1974-03-15
•
Granted: 1978-06-06
•
Expires: 1994-03-15
Abstract
Abstract 9-β-D-Arabinofuranosyl nucleotides of the following structure are disclosed: ##STR1## wherein AP is a 3' or 5' phosphorylated arabinofuranoside or the corresponding 3', 5' cyclic phosphate joined by a glycoside linkage to N 9 of the aglycon component of said nucleotide, and Z is H, C 1 -C 6 alkyl, C 7 -C 10 aralkoxy, or hydroxy. Compounds prepared according to the invention exhibit antiviral activity in vitro, while others are precursors useful in the synthesis of bioactive compounds.
Inventors
- 👤 Richard L. Tolman
- 👤 Robert W. Sidwell
- 👤 Ganapathi R. Revankar
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:40
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
74 words
Compounds of the structure: ##STR4## wherein Z is H or hydroxy; and one of X or Y is H and the other is ##STR5## or X and Y together are ##STR6## R 1 is OH, O--C 1 --C 6 -alkyl or OM; and R 2 is OH or OM; and M is ammonium, tri-ethyl ammonium, alkali metal, or alkaline earth metal; provided that when X is H, R 1 is not OH or OM.
Claim 2
Dependent Claim
74 words
Compounds of the structure: ##STR4## wherein Z is H or hydroxy; and one of X or Y is H and the other is ##STR5## or X and Y together are ##STR6## R 1 is OH, O--C 1 --C 6 -alkyl or OM; and R 2 is OH or OM; and M is ammonium, tri-ethyl ammonium, alkali metal, or alkaline earth metal; provided that when X is H, R 1 is not OH or OM.
Claim 3
Dependent Claim
36 words
Compounds of claim 1 of the strcture: ##STR7## wherein R 1 is --O--C 1 --C 6 -alkyl and R 2 is OH or OM and M is ammonium, tri-ethyl ammonium, alkali metal, or alkaline earth metal.
Claim 4
Dependent Claim
39 words
Compounds of claim 1 of the structure: ##STR8## wherein R 1 is OH, --O--C 1 --C 6 -alkyl or OM and R 2 is OH or OM and M is ammonium, tri-ethyl ammonium, alkali metal, or alkaline earth metal.
Claim 5
Dependent Claim
32 words
Compounds of claim 1 of the structure: ##STR9## wherein R 1 is OH, --O--C 1 --C 6 -alkyl or OM and M is ammonium, tri-ethyl ammonium, alkali metal, or alkaline earth metal.
Claim 6
Dependent Claim
3 words
9-β-D-Arabinofuranosylhypoxanthine-3' ,5'-cyclic phosphate.
Claim 7
Dependent Claim
3 words
9-β-D-Arabinofuranosylhypoxanthine-3' ,5'-cyclic phosphate.
Claim 8
Dependent Claim
1 words
9-β-D-Arabinofuranosylhypoxanthine-5'-O-methylphosphate.
Claim 9
Dependent Claim
1 words
9-β-D-Arabinofuranosylhypoxanthine-5'-O-methylphosphate.
Claim 10
Dependent Claim
3 words
9-β-D-Arabinofuranosyl-N 1 -hydroxyhypoxanthine-5'-phosphate.
Claim 11
Dependent Claim
3 words
9-β-D-Arabinofuranosyl-N 1 -hydroxyhypoxanthine-5'-phosphate.
Claim 12
Dependent Claim
1 words
9-β-D-Arabinofuranosylhypoxanthine-3'-phosphate.
Claim 13
Dependent Claim
1 words
9-β-D-Arabinofuranosylhypoxanthine-3'-phosphate.
Claim 14
Dependent Claim
1 words
9-β-D-Arabinofuranosyladenine-5'-O-methylphosphate.
Claim 15
Dependent Claim
1 words
9-β-D-Arabinofuranosyladenine-5'-O-methylphosphate.
Claim 16
Dependent Claim
1 words
9-β-D-Arabinofuranosyladenine-3'-phosphate.
Claim 17
Dependent Claim
1 words
9-β-D-Arabinofuranosyladenine-3'-phosphate.
Claim 18
Dependent Claim
27 words
An antiviral composition for the treatment of DNA virus infections containing as its active ingredient an effective amount of the compound 9-β-D-arabinofuranosylhypoxanthine 5'-phosphate in a pharmaceutical carrier.
Claim 19
Dependent Claim
27 words
An antiviral composition for the treatment of DNA virus infections containing as its active ingredient an effective amount of the compound 9-β-D-arabinofuranosylhypoxanthine 5'-phosphate in a pharmaceutical carrier.
Claim 20
Dependent Claim
42 words
An antiviral composition for the treatment of DNA virus-caused infections containing as its active ingredient an effective amount of a compound chosen from the group 9-β-D-arabinofuranosylhypoxanthine 5'--O--C 1 --C 6 alkyl phosphate, 9-β-D-arabinofuranosylhypoxanthine 3'-phosphate, and 9-β-D-arabinofuranosylhypoxanthine 3',5'-cyclic phosphate in a pharmaceutical carrier.
Claim 21
Dependent Claim
42 words
An antiviral composition for the treatment of DNA virus-caused infections containing as its active ingredient an effective amount of a compound chosen from the group 9-β-D-arabinofuranosylhypoxanthine 5'--O--C 1 --C 6 alkyl phosphate, 9-β-D-arabinofuranosylhypoxanthine 3'-phosphate, and 9-β-D-arabinofuranosylhypoxanthine 3',5'-cyclic phosphate in a pharmaceutical carrier.
Claim 22
Dependent Claim
47 words
A process of inhibiting the development of DNA virus-caused viral infections in warm-blooded animals comprising administering to said warm-blooded animals a pharmaceutical composition containing as the active component at least about 0.001 percent by weight, based on the total weight of the composition, the compound 9-β-D-arabinofuranosylhypoxanthine 5'-phosphate.
Claim 23
Dependent Claim
47 words
A process of inhibiting the development of DNA virus-caused viral infections in warm-blooded animals comprising administering to said warm-blooded animals a pharmaceutical composition containing as the active component at least about 0.001 percent by weight, based on the total weight of the composition, the compound 9-β-D-arabinofuranosylhypoxanthine 5'-phosphate.
Claim 24
Dependent Claim
62 words
A process of inhibiting the development of DNA virus-caused viral infections in warm-blooded animals comprising administering to said warm-blooded animals a pharmaceutical composition containing as the active component at least about 0.001 percent by weight, based on the total weight of the composition, a compound chosen from the group 9-β-D-arabinofuranosylhypoxanthine 5'--O--C 1 --C 6 alkyl phosphate, 9-β-D-arabinofuranosylhypoxanthine 3'-phosphate, and 9-β-D-arabinofuranosylhypoxanthine 3',5'-cyclic phosphate.
Claim 25
Dependent Claim
62 words
A process of inhibiting the development of DNA virus-caused viral infections in warm-blooded animals comprising administering to said warm-blooded animals a pharmaceutical composition containing as the active component at least about 0.001 percent by weight, based on the total weight of the composition, a compound chosen from the group 9-β-D-arabinofuranosylhypoxanthine 5'--O--C 1 --C 6 alkyl phosphate, 9-β-D-arabinofuranosylhypoxanthine 3'-phosphate, and 9-β-D-arabinofuranosylhypoxanthine 3',5'-cyclic phosphate.
References Cited (Backward Citations)
US3049536A
Cited
US3170917A
Cited
US3314938A
Cited
US3328389A
Cited
US3300478A
Cited
US3317512A
Cited
US3337530A
Cited
US3728329A
Cited
US3755296A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-06-05 | 1981-12-05 | 1982-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-06-05 | 1985-12-05 | 1986-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-06-05 | 1989-12-05 | 1990-06-06 | $7700.00 | Window Closed / Lapsed |